1. Home
  2. PGEN vs SAM Comparison

PGEN vs SAM Comparison

Compare PGEN & SAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Precigen Inc.

PGEN

Precigen Inc.

HOLD

Current Price

$5.64

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo Boston Beer Company Inc. (The)

SAM

Boston Beer Company Inc. (The)

SELL

Current Price

$183.62

Market Cap

1.9B

ML Signal

SELL

Company Overview

Basic Information
Metric
PGEN
SAM
Founded
1998
1984
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Beverages (Production/Distribution)
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.9B
IPO Year
2013
1996

Fundamental Metrics

Financial Performance
Metric
PGEN
SAM
Price
$5.64
$183.62
Analyst Decision
Buy
Hold
Analyst Count
5
11
Target Price
$8.33
$233.70
AVG Volume (30 Days)
5.5M
273.7K
Earning Date
05-13-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
95.45
EPS
N/A
N/A
Revenue
$230,981,000.00
$1,964,994,000.00
Revenue This Year
$1,115.92
$1.02
Revenue Next Year
$81.04
$1.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.47
$158.68
52 Week High
$6.04
$264.46

Technical Indicators

Market Signals
Indicator
PGEN
SAM
Relative Strength Index (RSI) 64.35 51.48
Support Level $3.32 $170.14
Resistance Level N/A $186.99
Average True Range (ATR) 0.34 6.44
MACD 0.06 1.52
Stochastic Oscillator 75.46 60.20

Price Performance

Historical Comparison
PGEN
SAM

About PGEN Precigen Inc.

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

About SAM Boston Beer Company Inc. (The)

Boston Beer is a top player in high-end malt beverages and adjacent categories in the US, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates almost all sales in the US.

Share on Social Networks: